bluebird bio/BLUE

$0.90

-4.11%
-
1D1W1MYTD1YMAX

About bluebird bio

bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).

Ticker

BLUE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Andrew Obenshain

Employees

323

Headquarters

Somerville, United States

bluebird bio Metrics

BasicAdvanced
$179M
Market cap
-
P/E ratio
-$0.74
EPS
0.84
Beta
-
Dividend rate
$179M
0.8393
$5.53
$0.85
7.3M
1.554
1.422
-16.08%
-47.81%
-21.5%
8.237
0.452
0.846
322.6%
87.09%

What the Analysts think about bluebird bio

Analyst Ratings

Majority rating from 14 analysts.
Hold

Price Targets

Average projection from 11 analysts.
362.22% upside
High $8.00
Low $1.00
$0.90
Current price
$4.16
Average price target

bluebird bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-582.92% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$12M
80.88%
Net income
-$72M
-1.65%
Profit margin
-582.92%
-45.63%

bluebird bio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.2%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.38
$0.21
-$0.67
-$0.66
-
Expected
-$0.44
-$0.37
-$0.72
-$0.67
-$0.65
Surprise
-187.16%
-156.76%
-6.37%
-2.2%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for bluebird bio stock?

bluebird bio (BLUE) has a market cap of $179M as of May 30, 2024.

What is the P/E ratio for bluebird bio stock?

The price to earnings (P/E) ratio for bluebird bio (BLUE) stock is 0 as of May 30, 2024.

Does bluebird bio stock pay dividends?

No, bluebird bio (BLUE) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next bluebird bio dividend payment date?

bluebird bio (BLUE) stock does not pay dividends to its shareholders.

What is the beta indicator for bluebird bio?

bluebird bio (BLUE) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the bluebird bio stock price target?

The target price for bluebird bio (BLUE) stock is $4.16, which is 362.22% above the current price of $0.9. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell bluebird bio stock

Buy or sell bluebird bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing